Nature | Polyclonal Selection of Immune Checkpoint Mutations in Thyroid Autoimmunity Drives B Cell Escape from Tolerance

This study reveals the cumulative selection of somatic mutations in PD-L1 and TNFRSF14 in autoreactive B cells, providing direct genetic evidence for the clonal evolution model in autoimmune diseases, suggesting that precision intervention strategies targeting tolerance pathways should take clonal heterogeneity into account.

 

Literature Overview

This paper, 'Polyclonal selection of immune checkpoint mutations in thyroid autoimmunity,' published in Nature, systematically investigates how B cells escape immune tolerance mechanisms in autoimmune thyroid disease (AITD). Using high-precision single-molecule sequencing technology (NanoSeq), the research team conducted a comprehensive screen for driver mutations in thyroid tissues from AITD patients, uncovering numerous independent clones carrying inactivating mutations in immune checkpoint genes. These findings redefine the molecular origins of autoimmune diseases, suggesting they are not solely triggered by systemic immune dysregulation, but rather arise from multi-stage somatic evolution of local B cell clones within inflammatory microenvironments.

Background Knowledge

Autoimmune thyroid diseases (such as Hashimoto’s thyroiditis and Graves’ disease) affect 5–10% of the global population, yet their molecular mechanisms remain incompletely understood. Although TPO and TG are known as major autoantigens and B cells play a central role in antibody production, the reasons for tolerance failure remain a key scientific question. While the PD-1/PD-L1 and HVEM/BTLA pathways are widely regarded as core peripheral tolerance checkpoints, their direct pathogenic role in AITD lacks somatic genetic evidence. Previous studies have been limited by the ability to detect low-frequency mutations, making it difficult to identify driver events in polyclonal lymphocytes. This study overcomes detection limits by applying NanoSeq technology to systematically explore the presence of functional somatic mutations in AITD tissues, thereby revealing the causal relationship between clonal selection and tolerance escape.

 

 

Research Methods and Experiments

The authors employed whole-exome and targeted NanoSeq sequencing, combined with laser-capture microdissection (LCM), single-cell DNA sequencing, methylation sequencing, spatial transcriptomics, and immunohistochemistry, to systematically screen for driver mutations in thyroid tissues from 14 AITD patients (including Hashimoto’s and Graves’ disease) and various control tissues. Key experimental components included using PBMCs and memory B cells as non-autoimmune controls, validating mutation specificity through deep sequencing, utilizing Xenium spatial transcriptomics to resolve clonal spatial distribution, and confirming via single-cell DNA sequencing that mutations occur within the B cell lineage while reconstructing clonal evolutionary trajectories. These multi-omics strategies ensured both accuracy in mutation detection and reliability in cellular origin.

Key Conclusions and Perspectives

• Dozens to hundreds of independent B cell clones carrying inactivating mutations in TNFRSF14 and CD274 (i.e., PD-L1) were detected in thyroid tissues of AITD patients, indicating polyclonal driver evolution. [Data discovery] + [guidance for future experimental directions]
• Although mutation frequency is low (typically <1% of cells), the cumulative proportion of B cells with mutations can reach 2–50%, indicating widespread tolerance escape. [Data discovery] + [guidance for future experimental directions]
• TNFRSF14 and CD274 mutations in AITD show strong positive selection signals and are absent in non-autoimmune controls, supporting their disease-specific pathogenic role. [Data discovery] + [guidance for future experimental directions]
• Single-cell sequencing confirmed mutations occur in B cells, with some clones harboring multiple driver mutations (e.g., biallelic inactivation), revealing multi-stage somatic evolutionary pathways. [Data discovery] + [guidance for future experimental directions]
• Spatial analysis shows that some germinal centers are dominated by a single mutated clone, suggesting local clonal expansion. [Data discovery] + [guidance for future experimental directions]

Research Significance and Prospects

This discovery fundamentally transforms our understanding of autoimmune diseases, redefining them from a 'systemic imbalance' to a 'local clonal evolution' process. This implies that future drug development should consider targeting specific mutant clones or their microenvironment rather than relying on broad-spectrum immunosuppression. Moreover, clinical monitoring could explore liquid biopsy approaches to track mutations in tolerance-related genes for early warning. For disease modeling, conditional B cell models carrying TNFRSF14 or PD-L1 mutations need to be developed to simulate clonal evolution processes.

 

 

Conclusion

This study, using high-precision sequencing, reveals a polyclonal, multi-stage somatic evolutionary pathway of B cell clones in thyroid autoimmunity, establishing inactivating mutations in TNFRSF14 and CD274 (PD-L1) as core mechanisms of tolerance escape. This finding not only explains why AITD patients are prone to progress to MALT lymphoma but also provides direct evidence for the 'clonal selection' model in autoimmune diseases. From bench to bedside, this research suggests the future development of precision monitoring tools targeting mutant clones and promotes personalized therapies targeting tolerance pathways. Particularly for patients with Hashimoto’s thyroiditis and Graves’ disease, screening for PD-L1 mutations in B cells could become a new tool for risk stratification, thereby optimizing treatment strategies and reducing overtreatment. This work sets a new paradigm for understanding the molecular basis of autoimmunity and holds profound translational value.

 

Pantelis A Nicola, Andrew R J Lawson, Alexandra Tidd, Nadia Schoenmakers, and Iñigo Martincorena. Polyclonal selection of immune checkpoint mutations in thyroid autoimmunity. Nature.